129139-48-6

Upstream product

• 69397-93-9 N-methyl-5-methoxy-2-nitroaniline 
• 446-38-8 2-fluoro-4-methoxy-1-nitro-benzene 
• 20628-18-6 1-acetamido-5-methoxy-2nitrobenzene 

Downstream Products

• 185428-18-6 rivoglitazone 
• 10394-42-0 6-methoxy-1-methylbenzimidazole 
• 657430-21-2 6-methoxy-1-methylbenzimidazole-2-methanol 
• 945023-35-8 6-methoxy-1-methyl-1H-benzo[d]imidazol-2-amine 
• 28249-63-0 6-methoxy-1-methyl-2-(2-methyl-3,5-dinitro-phenyl)-2,3-dihydro-1H-benzo[1,3,2]diazaborole 
• 4583-86-2 5-methoxy-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one 

Relevant academic research and scientific papers

Benzimidazole compound and application thereof

The invention relates to a benzimidazole compound and an application thereof. The structure of the benzimidazole compound is shown as a formula I, and the compound is used as a focal adhesion kinase inhibitor and shows relatively good focal adhesion kinase (FAK) inhibition activity. Meanwhile, the benzimidazole compound has stronger medicine effect and better pharmacokinetic property and/or toxicological characteristics, such as good brain/plasma ratio, good bioavailability, good metabolic stability, and reduced inhibition to respiratory action of mitochondria. The benzimidazole compound has agood clinical application prospect.

Benzimidazole- and benzothiazole-quinones: Excellent substrates for NAD(P)H:quinone oxidoreductase 1

A series of benzimidazole- and benzothiazole-quinones has been synthesized. The ability of these heterocyclic quinones to act as substrates for recombinant human NAD(P)H:quinone oxidoreductase (NQO1), a two-electron reductase upregulated in tumour cells,

Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym- may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Medicament Combinations for the Treatment of Respiratory Diseases

The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R1, X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

New betamimetics for the treatment of respiratory complaints

The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and R1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Benzimidazole derivatives, their preparation and their therapeutic use

Compounds of formula (I): STR1 [wherein: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethlyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and m is an integer from 1 to 5]; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.

Treatment of arteriosclerosis and xanthoma

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-?1-(4-2'-pyridylphenyl)ethylideneaminooxy!-ethoxy}benzyl)thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo?5,4-b!pyridin-2-yl-methoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride, 5-?4-(6-methoxy-l-methylbenzimidazol-2-ylmethoxy)benzyl!thiazolidine-2,4-dione, 5-?4-(l-methylbenzimidazol-2-ylmethoxy)benzyl!-thiazolidine-2,4-dione and 5-?4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy) benzyllthiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

Benzimidazole derivatives, their preparation and their therapeutic use

Compounds of formula (I): [in which: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxo-oxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and mis an integer from 1 to 5]; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.

Cycloalkyl or benzyl-6-substituted-quinoxalinediones

Heterocyclic dihydroxyquinoxaline compounds having the formula STR1 wherein R 1 is C 1-12 -alkyl, which may optionally be substituted by hydroxy, formyl, carboxy, carboxylic esters, amides or amines, C 3-8 -cycloalkyl, aryl, aralkyl; and wherein R 6 is, hydrogen, halogen, CN, CF 3, NO 2, or OR'', wherein R'' is C 1-4 -alkyl and R 5, R 7 and R 8 is hydrogen, provided R 6 is not CF 3, OCH 3, NO 2, C 1 or Br when R 1 is CH 3 ; orR 6 and R 7 independently are NO 2, halogen, CN, CF 3, or OR'', wherein R'' is C 1-4 -alkyl, and R 5 and R 8 are each hydrogen; orR 5 and R 6 together form a further fused aromatic ring, which may be substituted with halogen, NO 2, CN, CF 3 or OR'', wherein R'' is C 1-4 -alkyl, and R 7 and R 8 independently are hydrogen, halogen, CN, CF 3, NO 2 or OR'', wherein R'' is C 1-4 -alkyl; orR 7 and R 8 together form a further fused aromatic ring, which may be substituted with halogen, NO 2, CN, CF 3 or OR'', wherein R'' is C 1-4 -alkyl, and R 5 and R 6 independently are hydrogen, halogen, CN, CF 3, NO 2 or OR'', wherein R'' is C 1-4 -alkyl.The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use.The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.